{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Liver+Cancer&page=10", "query": { "condition": "Advanced Liver Cancer", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 527, "total_pages": 53, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Liver+Cancer&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Liver+Cancer&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-05T04:55:32.419Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Cancer", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Emibetuzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2014-03-07", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082210" }, { "nct_id": "NCT05176223", "title": "68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 Gozetotide", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2022-01-30", "completion_date": "2025-12-31", "has_results": true, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176223" }, { "nct_id": "NCT00335829", "title": "Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "chemotherapy", "type": "DRUG" }, { "name": "embolization therapy", "type": "DRUG" }, { "name": "hepatic artery infusion", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 26, "start_date": "2006-05", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2021-08-13", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00335829" }, { "nct_id": "NCT01835223", "title": "Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Adult Hepatocellular Carcinoma", "Non-Resectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Tivozanib (1mg)", "type": "DRUG" }, { "name": "Tivozanib (1.5mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2013-07-11", "completion_date": "2019-11-08", "has_results": true, "last_update_posted_date": "2020-10-28", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 2, "location_summary": "Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835223" }, { "nct_id": "NCT00537121", "title": "Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer", "Liver Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "vorinostat", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2006-11", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-06-28", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00537121" }, { "nct_id": "NCT00882180", "title": "Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ALN-VSP02", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alnylam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2009-03", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2011-08-24", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00882180" }, { "nct_id": "NCT01882946", "title": "Safety and Efficacy Study of DCVax-Direct in Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Tumor", "Metastatic Solid Tissue Tumors", "Liver Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Melanoma" ], "interventions": [ { "name": "DCVax-Direct", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Northwest Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2013-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-07", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 2, "location_summary": "Orlando, Florida • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01882946" }, { "nct_id": "NCT02562755", "title": "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma (HCC)" ], "interventions": [ { "name": "Pexastimogene Devacirepvec (Pexa Vec)", "type": "BIOLOGICAL" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SillaJen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 459, "start_date": "2015-10", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02562755" }, { "nct_id": "NCT00415155", "title": "A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "LY2181308", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2008-08", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2008-08-29", "last_synced_at": "2026-11-05T04:55:32.419Z", "location_count": 4, "location_summary": "Los Angeles, California • Hartford, Connecticut • Albuquerque, New Mexico + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00415155" } ] }